Funder: ALS Association
Due Dates (Anticipated): October 2025 (RFA opens) | November 2025 (LOI due) | February 2026 (Full proposal, by invitation)
Funding Amounts: Up to $1,000,000 total per award over 2–3 years; typical distributions: $500k/year (2-year) or $500k/$250k/$250k (3-year)
Summary: Supports early-stage clinical trials of novel or repositioned ALS therapeutics or imaging tracers, emphasizing strong biological rationale, biomarkers, and innovative approaches.
Key Information: Programs targeting TDP-43 and/or protein aggregation are of special interest in this cycle.